Rhythm Pharmaceuticals

Stories

FDA expands treatment options for obesity with rare and mainstream drug approvals

As of May 2026: Imcivree launches in largest indication; monitors GLP-1 competition in obesity space

For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.

Updated May 30